From UBS...
The Plasma Protein Therapeutics Association produces monthly data on plasma distribution volumes in the USA. According to its April figures, CSL’s immunoglobulin (IG) business grew 13.9% (12-month rolling basis). This was slightly up from March’s 13.8%.UBS forecasts a decline in plasma collection of -20% for the April-September period owing to covid-19 induced restrictions. This in turn reduces forecasts for IG/albumin volumes by -20% for the first half of FY21.The broker highlights every -5% reduction in plasma collections over a 6-month period translates to a circa -2% earnings downgrade for the year.The company will be releasing its FY20 results on August 19.UBS retains its Buy rating with a target price of $331.
From UBS...The Plasma Protein Therapeutics Association produces...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.56 |
Change
-4.190(1.40%) |
Mkt cap ! $142.8B | |||
| Open | High | Low | Value | Volume |
| $299.64 | $300.03 | $294.81 | $174.3M | 587.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2500 | $295.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.56 | 688 | 2 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |